<- Go Home
Mainz Biomed N.V.
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. It has a collaboration agreement with Thermo Fisher Scientific Inc. for the development of colorectal cancer screening product. The company was founded in 2008 and is based in Mainz, Germany.
Market Cap
$5.3M
Volume
168.0K
Cash and Equivalents
$977.8K
EBITDA
-$21.6M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
$541.0K
Profit Margin
58.98%
52 Week High
$1.79
52 Week Low
$0.19
Dividend
N/A
Price / Book Value
-1.28
Price / Earnings
-0.18
Price / Tangible Book Value
-0.72
Enterprise Value
$12.6M
Enterprise Value / EBITDA
-0.59
Operating Income
-$22.0M
Return on Equity
4333.72%
Return on Assets
-99.24
Cash and Short Term Investments
$977.8K
Debt
$8.3M
Equity
-$4.1M
Revenue
$917.2K
Unlevered FCF
-$11.9M
Sector
Biotechnology
Category
N/A
Hedge Funds that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Professional Funds that own this company (and many other perks).
Upgrade to Yellowbrick PremiumYellowbrick Portfolios that own this stock
PREMIUM
Upgrade to Yellowbrick Premium to unlock the Yellowbrick portfolios that own this company (and many other perks).
Upgrade to Yellowbrick Premium